IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

AGHEMO, ALESSIO MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.623
NA - Nord America 9.360
AS - Asia 8.376
Continente sconosciuto - Info sul continente non disponibili 1.370
SA - Sud America 831
AF - Africa 201
OC - Oceania 55
Totale 31.816
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.842
GB - Regno Unito 4.094
DE - Germania 2.448
CN - Cina 2.314
SG - Singapore 2.209
IT - Italia 1.633
BD - Bangladesh 1.059
SE - Svezia 871
RU - Federazione Russa 728
HK - Hong Kong 645
VN - Vietnam 623
BR - Brasile 601
IN - India 427
FR - Francia 397
CA - Canada 381
TR - Turchia 321
IE - Irlanda 241
UA - Ucraina 236
NL - Olanda 227
FI - Finlandia 205
KR - Corea 189
EU - Europa 114
ID - Indonesia 113
DK - Danimarca 103
JP - Giappone 98
CO - Colombia 79
ES - Italia 69
MX - Messico 62
PL - Polonia 61
CI - Costa d'Avorio 57
BE - Belgio 56
AR - Argentina 51
AU - Australia 43
GR - Grecia 43
CH - Svizzera 41
TW - Taiwan 38
RO - Romania 37
IQ - Iraq 34
UZ - Uzbekistan 32
EC - Ecuador 30
EG - Egitto 30
IR - Iran 30
AT - Austria 29
PK - Pakistan 27
TH - Thailandia 27
ZA - Sudafrica 27
CL - Cile 23
PH - Filippine 23
KH - Cambogia 21
IL - Israele 19
JO - Giordania 19
MA - Marocco 19
AE - Emirati Arabi Uniti 17
JM - Giamaica 16
PT - Portogallo 16
SA - Arabia Saudita 16
VE - Venezuela 15
TN - Tunisia 14
HU - Ungheria 13
PE - Perù 13
CR - Costa Rica 11
LT - Lituania 11
NP - Nepal 11
MY - Malesia 10
NO - Norvegia 10
ET - Etiopia 9
PS - Palestinian Territory 9
TT - Trinidad e Tobago 9
UG - Uganda 9
BO - Bolivia 8
KZ - Kazakistan 8
NZ - Nuova Zelanda 8
CZ - Repubblica Ceca 7
AZ - Azerbaigian 6
HN - Honduras 6
KE - Kenya 6
LV - Lettonia 6
OM - Oman 6
UY - Uruguay 6
DZ - Algeria 5
EE - Estonia 5
GT - Guatemala 5
MK - Macedonia 5
MQ - Martinica 5
NG - Nigeria 5
RS - Serbia 5
AL - Albania 4
BB - Barbados 4
DO - Repubblica Dominicana 4
KG - Kirghizistan 4
MD - Moldavia 4
PA - Panama 4
PR - Porto Rico 4
PY - Paraguay 4
AO - Angola 3
BG - Bulgaria 3
LB - Libano 3
LK - Sri Lanka 3
LU - Lussemburgo 3
SK - Slovacchia (Repubblica Slovacca) 3
Totale 30.507
Salva come PNG Salva come JPEG
Città #
Southend 3.730
Singapore 1.273
Ashburn 954
Chandler 670
Hong Kong 566
San Jose 510
Frankfurt am Main 454
Milan 435
Beijing 419
Seattle 400
Dallas 350
Council Bluffs 333
Santa Clara 300
Princeton 283
Hanover 274
Los Angeles 268
Wilmington 268
New York 266
Fairfield 238
Dublin 234
Ann Arbor 212
Ho Chi Minh City 193
Toronto 189
Hanoi 171
Woodbridge 163
Jacksonville 161
Dearborn 159
Boardman 141
Nanjing 141
Buffalo 138
Lauterbourg 130
Houston 126
Bengaluru 122
Guangzhou 121
Mountain View 114
Des Moines 99
Shanghai 99
Moscow 97
Redmond 95
Rome 94
Cambridge 90
Andover 83
Redwood City 82
Munich 76
Helsinki 74
Phoenix 74
Berlin 64
Columbus 64
Jinan 63
Hefei 62
Sakarya 61
Serra 60
Jakarta 59
São Paulo 59
Istanbul 58
Abidjan 57
Tokyo 57
Ottawa 56
Somerville 53
Bogotá 52
The Dalles 52
Naples 51
Tianjin 48
Cangzhou 46
Shenyang 46
Brussels 44
Nanchang 44
Saint Petersburg 43
London 40
Da Nang 39
Grafing 39
Changsha 36
Mumbai 34
Warsaw 34
San Diego 33
Turin 32
Zhengzhou 32
Athens 30
Brooklyn 30
Jiaxing 29
Atlanta 28
Eitensheim 28
Shenzhen 28
Washington 28
Montreal 27
Chengdu 25
Chicago 25
Hangzhou 25
Hebei 25
Taipei 24
Wuhan 24
Fuzhou 23
Seoul 23
Orem 22
Ankara 21
Bologna 21
Haiphong 21
Nuremberg 21
Phnom Penh 21
Belo Horizonte 20
Totale 17.556
Salva come PNG Salva come JPEG
Nome #
COVID-19 and liver disease 872
Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection 729
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 648
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals 453
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 438
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients 423
Real life experiences in HCV management in 2018 415
Prevalence of psychiatric disorders during PEG – Interferon and Ribavirin therapy in patients with chronic hepatitis HCV-correlated 409
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 362
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease 334
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 334
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 332
High rates of 30-day mortality in patients with cirrhosis and COVID-19 325
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 322
Indolent B-cell lymphomas treated upfront with antiviral therapy : a series of 13 patients 318
Donor/recipient match of IL28B to predict interferon response in recurrent hepatitis C 305
Liver stiffness measurement reliability and main determinants of point shear-wave elastography in patients with chronic liver disease 303
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 283
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegykated interferon-α2A in chronic hepatitis C : an in vitro and in vivo study 279
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 279
Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients 278
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir 266
S1pr2 is a key mediator of endoplasmic reticulum stress in NAFLD/ NASH pathogenesis 266
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C 263
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 259
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 258
Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis 257
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 252
US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C 250
Recovery after L-DOPA treatment in peg-interferon and ribavirin induced parkinsonism 249
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 248
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 247
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? 246
Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis 243
New horizons in hepatitis C antiviral therapy with direct-acting antivirals 243
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C 242
Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method 241
High levels of factor VIII and risk of extra-hepatic portal vein obstruction 239
Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients 238
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 237
Allelic inhibition of displacement activity : a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 236
The natural history of portal hypertension in patients with HCV related compensated cirrhosis undergoing interferon ribavirin therapy 235
Genotype dependent pattern of peginterferon alfa-2b/ribavirin treatment failure in hepatiti sC virus infected patients with cirrhosis : a single center study of 471 naive patients 234
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study 234
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients 233
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 233
Hepatorenal syndrome and novel advances in its management 232
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 232
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 230
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 225
Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis 225
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 225
In vivo and in vitro effect of ribavirin and interferon on erythropoiesis in patients with hepatitis C 225
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 224
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection : a predictor of spontaneous viral clearance and sustained virological response 222
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 222
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 221
Genotype dependent pattern of Peginterferon alfa-2B/Ribavirin treatment failure in hepatitis C virus infected patients with cirrhosis : a single centre study of 471 naïve patients 219
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 216
NPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 215
Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection 215
Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3α hepatitis C virus infection 212
Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients : a single-centre study 212
The diagnostic accuracy of fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with an SVR 211
The influence of liver fibrosis on the outcome of pegylated interferon and ribavirin anti-hac therapy : a sub-analysis of the mist study 210
Renal safety in 3264 HCV patients treated with DAA-based regimens : results from a large Italian real-life study 209
A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients 208
Hepatitis C virus genotypes and patterns of peginterferon alfa-2b/ribavirin treatment failure in patients with cirrhosis : a single center study of 471 naïve patients 207
Effect of the PNPLA3 I148M polymorphism on the outcome of peg-interferon plus ribavirin treatment in chronic hepatitis C 207
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-α2a in chronic hepatitis C: an in vitro and in vivo study 207
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 206
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 205
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 203
Individualized hepatocellular carcinoma risk : the challenges for designing successful chemoprevention strategies 203
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 197
In vivo and in vitro effect of ribavirin and pegylated-interferon on erythropoiesis in patients with hepatitis C 196
Increased risk of hepatocellular carcinoma in HCV (+) non responder cirrhotics with high liver cell proliferation 196
Increased survival of patients with HCV-related cirrhosis with a long-term response to interferon therapy 195
PNPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 195
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure 192
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 189
Liver cell proliferation and liver cancer risk in patients with hepatitis C virus-related cirrhosis under antiviral treatment 188
Anti-TNF drugs in patients with hepatitis B or C virus infection : safety and clinical management 185
Interferoni pegilati nel trattamento dei pazienti con epatite cronica HCV : esperienze a confronti 184
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 181
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 180
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 180
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 180
Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis 180
Evaluation of liver disease in a cohort of patients affected by thalassemia intermedia 178
Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis 177
The natural history of hepatic macroregenerative nodules developing in cirrhotic patients during surveillance with ultrasound (US) 175
Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy 175
Is there an 'ideal' diet for patients with NAFLD? 173
Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation 172
Prospective study of dysplastic nodules in cirrhosis : correlation with CT vascular pattern, histology and development of hepatocellular carcinoma 171
Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C 171
Meccanismi patogenetici dell'anemia in corso di terapia antivirale in pazienti con epatite cronica HCV correlata 170
Assessing long-term treatment efficacy in chronic hepatitis B and C : Between evidence and common sense 169
Lack of alanine aminotransferase normalization in patients with an anti-hcv virological response during pegylated interferon and ribavirin therapy : a sub-analysis of the mist study 168
Totale 25.355
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.913
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.913
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.118 0 0 116 152 208 207 219 210 243 286 134 343
2022/20232.287 286 286 197 281 232 423 66 106 232 41 101 36
2023/20241.572 50 131 91 111 375 115 109 112 40 87 159 192
2024/20253.554 165 356 76 428 287 135 125 321 213 365 346 737
2025/20268.719 780 409 824 552 724 533 1.088 440 803 574 1.170 822
2026/20271.271 672 597 2 0 0 0 0 0 0 0 0 0
Totale 31.816